Cyclotron Arrival at MPI Research's Translational Imaging Center - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Cyclotron Arrival at MPI Research's Translational Imaging Center



MPI Research and 3D Imaging reported the arrival of the cyclotron, a particle accelerator, at its new Translational Imaging Center in Mattawan, Michigan. The radioisotopes produced from the cyclotron will be used to visualize, characterize, and quantify biological, chemical, and physiological processes at the cellular and molecular level in vivo. The cyclotron expands the portfolio of available radioisotopes that can be used in molecular imaging and provides drug developers a way to track drugs.

Products from the cyclotron will become commercially available when the Translational Imaging Center opens in May 2014.

Source: MPI Research

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes

Click here